Interviews

Robert Cerwinski, JD, partner at Goodwin, discusses a petition before the Supreme Court challenging the constitutionality of inter partes review.

Brandon Shank, PharmD, MPH, BCOP, Clinical Pharmacy Specialist, discusses the need for pharmacy schools to adapt their curriculum to address biosimilar treatments.

Robert Cerwinski, JD, partner at Goodwin, discusses the potential for government agencies to weigh in on pay-for-delay settlements in the biosimilars space.

Brandon Shank, PharmD, MPH, BCOP, Clinical Pharmacy Specialist, discusses the potential for reimbursement challenges with biosimilars.

Bruce A. Feinberg, DO, CMO, Cardinal Health Specialty Solutions, discusses the importance of patient education on biosimilar treatments.

Robert Cerwinski, JD, Partner at Goodwin, discusses the impact of the recent Supreme Court ruling in TC Heartland v Kraft on biosimilar litigation.

Brandon Shank, PharmD, MPH, BCOP, Clinical Pharamcy Specialist, discusses the merits of the current biosimilar naming system.

Kashyap Patel, MD, Medical Oncologist, Carolina Blood and Cancer Care, discusses the potential impact of biosimilar drugs on Medicare Part D drug pricing.

Marcus H. Snow, MD, Assistant Professor Rheumatology, University of Nebraska, discusses concerns about automatic substitution of biosimilars for reference products.

Robert Cerwinski, JD, Partner at Goodwin, discusses current infliximab litigation.

Bruce A. Feinberg, DO, CMO, Cardinal Health Specialty Solutions, discusses biosimilar labeling and concerns with extrapolation.

Robert Cerwinski, JD, Partner at Goodwin, discusses the potential for an upcoming executive order on drug pricing.

Robert Cerwinski, JD, Partner at Goodwin, discusses the “big 3” biologics for inter partes review: Herceptin, Rituxan, and Humira.

Ha Kung Wong, JD, Partner at Fitzpatrick, Cella, Harper and Scinto, discusses current BPCIA litigation concerning biosimilar products.

Marcus H. Snow, MD, Assistant Professor Rheumatology, University of Nebraska, discusses the recent launch of a new biosimilar infliximab, Renflexis, in the United States.

Robert Cerwinski, JD, Partner at Goodwin, discusses what becomes of the BPCIA if the Affordable Care Act is repealed by Congress.

Brandon Shank, PharmD, MPH, BCOP, Clinical Pharmacy Specialist, discusses the importance of pharmacist education on biosimilar treatments.

Ha Kung Wong, JD, Partner at Fitzpatrick, Cella, Harper and Scinto, discusses whether the FDA might clarify its stance on the BPCIA.

Marcus H. Snow, MD, Assistant Professor of Rheumatology, University of Nebraska, discusses the use of biosimilar treatments in children.

Ha Kung Wong, JD, Partner at Fitzpatrick, Cella, Harper and Scinto, discusses whether the PTAB might invalidate more patents concerning dosing and frequency of biologics, as it did with claims 1 to 5 of AbbVie's '135 patent for Humira.

Ha Kung Wong, JD, Partner at Fitzpatrick, Cella, Harper and Scinto, discusses the use of inter partes review (IPR) in the biosimilars context.

Ha Kung Wong, JD, Partner at Fitzpatrick, Cella, Harper and Scinto, discusses incentives for biosimilar applicants to engage in the BPCIA "patent dance" after the SCOTUS ruling in Sandoz v Amgen.

Ha Kung Wong, JD, Partner at Fitzpatrick, Cella, Harper and Scinto, discusses the questions left unresolved by SCOTUS in the Sandoz v Amgen ruling.

Joseph P. Fuhr, Jr, PhD, professor emeritus, Widener University, discusses the impact that biosimilars will have on the healthcare industry.

Joseph P. Fuhr, Jr, PhD, professor emeritus, Widener University, discusses interchangability in biosimilars.

Joseph P. Fuhr, Jr, PhD, professor emeritus, Widener University, discusses biosimilar competition and its effect on market share and price.

Joseph P. Fuhr, Jr, PhD, professor emeritus, Widener University, looks to evidence from Europe to predict US biosimilar cost-savings.

Joseph P. Fuhr, Jr, PhD, professor emeritus, Widener University, sees a limited economic impact for biosimilars given current patent disputes.

Joseph P. Fuhr, Jr, PhD, professor emeritus, Widener University, sees value in stakeholder education about biosimilar products.